Idera Pharmaceuticals, Inc.
Immune modulation with TLR9 agonists for cancer treatment
Last updated:
Abstract:
The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
Status:
Grant
Type:
Utility
Filling date:
30 Aug 2019
Issue date:
17 Nov 2020